Dongsheng Tu
机构: Professor of Biostatistics, Queen's University at Kingston, Canada
每年引用次数
引用次数
引用: 50,542
H-指数: 84
I10-指数 : 235
出版物: 544
NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction.
Beverly Moy , Dongsheng Tu , Harriet Richardson , Elizabeth Maunsell
Journal of Clinical Oncology 31 6557 -6557
2013
Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17.
Stephanie Yasmin Brule , Derek J. Jonker , Christos Stelios Karapetis , Christopher J. O'Callaghan
Journal of Clinical Oncology 31 3528 -3528
19
2013
Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.
Michael M. Vickers , Dongsheng Tu , Chee Lee , Paul Wheatley-Price
Journal of Clinical Oncology 31 4053 -4053
1
2013
Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial.
Daniel John Renouf , Wendy Parulekar , Julia Grigorieva , Dongsheng Tu
Journal of Clinical Oncology 31 ( 15) 4061 -4061
2
2013
Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.
Vikki Ho , , Romain Pasquet , Shaman Luo
Breast Cancer Research and Treatment 183 ( 3) 705 -716
2020
Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
Graeme G. Duncan , Joel B. Epstein , Dongsheng Tu , Samy El Sayed
Head and Neck-journal for The Sciences and Specialties of The Head and Neck 27 ( 5) 421 -428
106
2005
Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
Maggie C.U. Cheang , Miguel Martin , Torsten O. Nielsen , Aleix Prat
Oncologist 20 ( 5) 474 -482
78
2015
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2‐Positive Metastatic Breast Cancer (CCTG IND.229)
Stephen Chia , Phillipe L Bedard , John Hilton , Eitan Amir
Oncologist 24 ( 11) 1439 -1445
36
2019
Testing the Homogeneity of Two Survival Functions Against a Mixture Alternative Based on Censored Data
Liting Zhu , Xianming Tan , Dongsheng Tu
Communications in Statistics - Simulation and Computation 39 ( 4) 767 -776
2010
Permutation Methods for Comparing the Accuracy of Nested Prediction Models in Survival Analysis
Wenyu Jiang , Nathalie C. Moon , Bingshu E. Chen , Dongsheng Tu
Communications in Statistics - Simulation and Computation 45 ( 8) 2691 -2708
1
2016
A Bartlett type correction for Wald test in Cox regression model
Xiao Li , Yaohua Wu , Dongsheng Tu
Statistics & Probability Letters 78 ( 16) 2614 -2622
3
2008
O-248 How should palliation be measured — illustrative examples from the NCIC CTG palliative thoracic radiation trial
Michael D. Brundage , Andrea Bezjak , Dongsheng Tu , Michael J. Palmer
Lung Cancer 41
2003
On the use of the ratio or the odds ratio of cure rates in therapeutic equivalence clinical trials with binary endpoints
Dongsheng Tu
Journal of Biopharmaceutical Statistics 8 ( 2) 263 -282
31
1998
Weighted rank tests for noninferiority hypotheses based on paired survival times.
Huan Jin , Naiqing Zhao , Dongsheng Tu
Journal of Biopharmaceutical Statistics 23 ( 2) 432 -446
2013
Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study
Andrea Bezjak , Dongsheng Tu , Monica Bacon , David Osoba
Journal of Clinical Oncology 22 ( 22) 4595 -4603
49
2004
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker , Louise Nott , Takayuki Yoshino , Sharlene Gill
The Lancet Gastroenterology & Hepatology 3 ( 4) 263 -270
55
2018
Innovations in the Management of Musculoskeletal Pain With Alpha-Lipoic Acid (IMPALA Trial): Study protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia Pain.
Ian Gilron , Dongsheng Tu , Ronald Holden , Tanveer Towheed
JMIR Research Protocols 6 ( 3)
5
2017
Pain Improvement With Novel Combination Analgesic Regimens (PAIN-CARE): Randomized Controlled Trial Protocol
Ian Gilron , Dongsheng Tu , Ronald Holden , Alan C Jackson
JMIR Research Protocols 6 ( 6)
3
2017
Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain
Ian Gilron , Dongsheng Tu , Ronald Holden , Tanveer Towheed
JMIR Research Protocols 6 ( 8)
1
2017
A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy.
Ian Gilron , Elizabeth Orr , Dongsheng Tu , Peter J. OʼNeill
Pain 113 ( 1) 191 -200
172
2005
Lois Shepherd Lesley Seymour Kathleen I. Pritchard C Karapetis John Zalcberg Jeremy Shapiro Timothy Price Christopher J O'Callaghan Michael Brundage Wendy R. Parulekar Ian Gilron John Goffin Lillian Siu Ronald R. Holden Nancy E Davidson Penelope Bradbury Stephen KL Chia Zee Chung-Ying Benny Ming Tsao Sharlene Gill